CARGO TherapeuticsNASDAQ: CRGX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

13 November 2023

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$741.51 M
-46%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector
-50%vs. 3y high
54%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 19 Nov 2024 21:20:00 GMT
$16.11+$0.06(+0.37%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CRGX Latest News

Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week
fool.com16 August 2024 Sentiment: POSITIVE

The cancer-focused biotech published its second-quarter results. Its loss was much narrower than analysts had expected.

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director
globenewswire.com04 June 2024 Sentiment: POSITIVE

CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director

CARGO Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com28 May 2024 Sentiment: POSITIVE

SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences.

What Makes CARGO Therapeutics, Inc. (CRGX) a New Buy Stock
zacks.com22 May 2024 Sentiment: POSITIVE

CARGO Therapeutics, Inc. (CRGX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts See a 56.26% Upside in CARGO Therapeutics, Inc. (CRGX): Can the Stock Really Move This High?
zacks.com22 May 2024 Sentiment: POSITIVE

The consensus price target hints at a 56.3% upside potential for CARGO Therapeutics, Inc. (CRGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

CARGO Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewsWire03 January 2024 Sentiment: POSITIVE

SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California.

Cargo Therapeutics IPO prices at $15 a share, low end of proposed range
Market Watch10 November 2023 Sentiment: NEUTRAL

Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, said late Thursday its initial public offering priced at $15 a share, the low end of its range. The company sold 18.8 million shares to raise $282 million at a valuation of $580.5 million.

IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO
Seeking Alpha06 November 2023 Sentiment: POSITIVE

Cargo Therapeutics, Inc. has filed for an IPO to raise $300 million for the development of its drug candidates for large B cell lymphoma cancer and other B cell malignancies. The IPO appears reasonably priced, but biopharma IPOs have performed poorly in the recent IPO environment. The market for treatments of diffuse large B-cell lymphoma is expected to reach $7.9 billion by 2030, driving the growth of CARGO Therapeutics.

Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 each
Market Watch06 November 2023 Sentiment: POSITIVE

Cargo Therapeutics CRGX, , a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $17 each. The company would raise $319.6 million at the top of that range at a valuation of $656.2 million.

Cargo Therapeutics Begins $100 Million IPO Rollout
Seeking Alpha23 October 2023 Sentiment: POSITIVE

Cargo Therapeutics, Inc. has filed for a $100 million IPO to develop improved CAR T-cell therapy for large B-cell lymphoma. The company's lead candidate, CRG-022, is in Phase 2 trials for the treatment of Refractory/Relapsed LBCL. The market for treatments of diffuse large B-cell lymphoma is forecasted to reach $7.9 billion by 2030, so Cargo Therapeutics is operating in a moderately growing market.

What type of business is CARGO Therapeutics?

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

What sector is CARGO Therapeutics in?

CARGO Therapeutics is in the Healthcare sector

What industry is CARGO Therapeutics in?

CARGO Therapeutics is in the Biotechnology industry

What country is CARGO Therapeutics from?

CARGO Therapeutics is headquartered in United States

When did CARGO Therapeutics go public?

CARGO Therapeutics initial public offering (IPO) was on 13 November 2023

What is CARGO Therapeutics website?

https://cargo-tx.com

Is CARGO Therapeutics in the S&P 500?

No, CARGO Therapeutics is not included in the S&P 500 index

Is CARGO Therapeutics in the NASDAQ 100?

No, CARGO Therapeutics is not included in the NASDAQ 100 index

Is CARGO Therapeutics in the Dow Jones?

No, CARGO Therapeutics is not included in the Dow Jones index

When was CARGO Therapeutics the previous earnings report?

No data

When does CARGO Therapeutics earnings report?

The next expected earnings date for CARGO Therapeutics is 21 March 2025